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Surgery offers the best chance of cure for patients with NSCLC,
although no more than 20% are operable. Overall surgical 5-year
survival rates are 55% for stage I, 25% for stage II, and 20% for stage
III disease (Mountain, 1977); patients with completely resected T3
tumours without mediastinal node involvement have a slightly better
outlook with approximately 40% 5-year survival (McCormack et al,
1987). These results can at best be described as moderate and it is
likely that many surgical patients would accept the option of addi-
tional treatment to try to improve their outlook (Slevin et al, 1990).
Randomized trials of post-operative adjuvant chemotherapy in
NSCLC have shown some prolongation of disease-free survival
with cisplatin-containing schedules (Holmes et al, 1986; Lad et al,
1988; Niiranen et al, 1992). A meta-analysis of eight such trials
has shown a 13% reduction in the risk of death, corresponding to
an absolute survival benefit of around 5% at 5 years (Non-small
Cell Lung Cancer Collaborative Group, 1995). A value judgement
is required on the clinical benefit of such treatment, and it seems
unlikely that significant further progress will be made with post-
operative therapy using currently available drugs.
Pre-operative chemotherapy is currently being investigated in
several tumour types including NSCLC, breast cancer and gastric
cancer. In NSCLC, most pre-operative chemotherapy studies have
been carried out in patients with stage IIIA disease. In non-
randomized studies, response rates have ranged from 50% to 
75% with occasional (10%) complete remissions; subsequent
resectability rates of 65–90% and 3–5-year survival rates of
17–40% have been reported (Faber et al, 1989; Skarin et al, 1989;
Weiden et al, 1991; Burkes et al, 1992; Strauss et al, 1992; Martini
et al, 1993). The heterogeneity of entry criteria and the lack of data
from randomized trials make these results difficult to interpret, but
they make the important point that the majority of such patients
appear to have chemosensitive disease prior to surgery. Two small
randomized trials have compared surgery with or without pre-
operative chemotherapy in patients with stage IIIA disease, each
with similar and strikingly positive results in favour of chemo-
therapy. In the first study, median survival was 26 months for
patients treated with pre-operative chemotherapy, compared with
8 months for patients treated with surgery alone (Rosell et al,
1994). The second study reported respective median survivals of
64 months vs 11 months (Roth et al, 1994).
These results, although encouraging, must be interpreted with
caution because of the small number of patients randomized. They
emphasize the need for a large multi-centre randomized trial, and
we felt that this should involve all patients with operable lung
cancer. Such an approach is novel and is associated with several
uncertainties. These include the question of acceptability of pre-
operative chemotherapy to both patient and doctor, the potential
for unacceptable chemotherapy-induced toxicity prior to surgery,
and the possibility of disease progression during chemotherapy.
We therefore decided to carry out a small randomized pilot
feasibility study to address these issues, using three pre-operative
cycles of MVP (mitomycin-C, vinblastine and cisplatin). This is a
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Correspondence to: I E Smithschedule which we have already shown to be active and well toler-
ated in advanced/metastatic NSCLC (Ellis et al, 1995). The
primary aim of this pilot study was to assess feasibility of, and
compliance with, pre-operative chemotherapy. The secondary
aims were to assess response, symptom control, performance
status, resectability and extent of surgery, side effects, and any
technical difficulties that might arise with surgery following
chemotherapy. We were also interested in assessing the quality of
life of patients during the treatment schedule. We report our results
here.
MATERIALS AND METHODS
Patients
Patients with previously untreated, histologically proven, NSCLC
were invited to enter the study. Patient entry criteria were: a
tumour considered to be resectable (i.e. stage I, II, or IIIA); a
World Health Organization (WHO) performance status of 0–1;
fitness for both the chemotherapy regimen and the proposed
thoracic surgery and no history of prior malignancy. A haemato-
logical and biochemical screen was performed and renal function
was assessed by creatinine clearance. The clearance was measured
either by ethylenediamine tetra-acetic acid (EDTA) scan, or by the
Cockcroft and Gault formula (Cockcroft and Gault, 1976).
Radiological assessment of the tumour was required by both chest
X-ray (CXR) and chest computed tomography (CT) scan. If there
was radiological evidence of mediastinal node involvement (N2),
or chest wall plus hilar disease (T3N1), or if radiological staging
was unclear, then mediastinoscopy and biopsy was performed. A
bone scan was performed to rule out bony metastases. Patients
accepting entry were required to sign a written consent form which
had been approved by the ethics committee at each participating
institution.
Chemotherapy regimen
The chemotherapy regimen consisted of mitomycin-C 8 mg m–2,
vinblastine 6 mg m–2 and cisplatin 50 mg m–2 given every 3 weeks
for three cycles (the mitomycin-C was only given in cycles 1 and
2). A strict hydration regime was followed consisting of 1 l of
normal saline plus 10 mmol of MgSO4 plus 40 mg of frusemide
prior to chemotherapy, with a further 1.5 l of normal saline 
with a total of 15 mmol of MgSO4 and 30 mmol of KCl as
postchemotherapy hydration. Anti-emetic prophylaxis consisted of
8 mg of dexamethasone with 3 mg of granisetron given i.v. prior to
chemotherapy with oral dexamethasone and oral domperidone to
take home. Chemotherapy was only administered if adequate
haematological recovery had occurred (neutrophil count > 1500
mm–3 and platelet count > 100 000 mm–3). If recovery had not
occurred, treatment was delayed for a week. If there was a 2-week
or more delay, than a 25% dose reduction was required. Creatinine
clearance was calculated prior to each cycle, with the cisplatin
dose adjusted if the clearance fell by more than 50% but remained
greater than 60 ml min–1. If the clearance fell by more than 50% of
the starting value, or to less than 60 ml min–1, then cisplatin was to
be substituted by carboplatin; the dose determined by the Calvert
formula (Calvert et al, 1989) with a desired area under curve
(AUC) of 4.
Assessment of toxicity and response
Chemotherapy-related toxicity was assessed and recorded after
each cycle of treatment. Toxicity was measured using the WHO
guidelines (Miller et al, 1981). Peri-operative and post-operative
complications were documented by the surgical team. Patients
were assessed both clinically and with CXR prior to each cycle of
treatment. Symptomatic response and WHO performance status
were recorded. Symptomatic response was graded as complete,
partial, no change, or progressive according to the patient’s own
assessment. A chest CT scan was performed following the last
cycle of chemotherapy to determine the radiological response.
Responses were graded according to standard International Union
Against Cancer criteria (Hayward et al, 1977). In addition, a minor
response was recorded if there was a reduction in size of the index
lesion of between 25% and 50% of the sum of the products of the
maximum diameter and a perpendicular diameter. Any patients
with evidence of clinical and/or radiological progression were 
to be removed from study and to undergo immediate thoracic
surgery.
Pathological response was assessed by the on-site histopatholo-
gist. Pathological complete response was defined as absence of
any tumour in the surgical specimen. Partial response was defined
as the presence of only small residual foci of tumour cells, or the
presence of significant areas of tumour necrosis throughout the
surgical specimen. No change was defined as the presence of large
areas of identifiable tumour cells in the surgical specimen with
minimal evidence of tumour necrosis.
All patients receiving pre-operative chemotherapy were asked
to complete European Organisation for Research and Treatment of
Cancer (EORTC) QL Core 30 Quality of Life questionnaires prior
to chemotherapy, after completion of the three cycles, and then at 3
months post-surgery. Patients in the surgery-only arm were also
asked to complete EORTC QL Core 30 Quality of Life question-
naires prior to surgery, and at 1 and 3 months after surgery.
RESULTS
Between July 1995 and May 1997, 96 patients were assessed for
entry to this study; 56 were excluded because of poor performance
status, comorbidity, previous cancers, or were found to be inoper-
able at mediastinoscopy. Of the 40 eligible patients, 22 (55%)
consented to participate and 11 were randomized to each arm of
the study. Of the remaining 18 patients, 17 gave as the reason for
refusal to participate their concerns over further ‘delay’, and their
preference for immediate surgery. One patient refused on the basis
of a relative’s ‘bad’ experience with chemotherapy. Patient demo-
graphics are shown in Table 1.
All 11 patients randomized to the chemotherapy arm received
the planned three cycles of treatment. The median time between
randomization and surgery for the chemotherapy-treated patients
was 76.5 days (69–85 days), and for surgery-alone patients was 10
days (1–25 days).
One patient, initially assessed as operable and entered into the
study, was considered on pre-operative evaluation to have been
inoperable from presentation. Thus, the patient did not proceed to
surgery. The patient had been randomized to, and received, three
cycles of chemotherapy, and had a minor radiological response.
This patient was included in the assessment of toxicity, perfor-
mance status, radiological response and follow-up.
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Toxicity
Significant chemotherapy-related toxicity was minimal. There
were no WHO grade 3 or grade 4 level toxicities. No admissions
were required due to effects of the treatment and there were no
chemotherapy dose reductions or dose delays. The most frequently
noted toxicities were all of grade 1 level: nausea and vomiting
(45% of patients), lethargy (36%), and alopecia and constipation
(27%). Haematological toxicity did not appear to be a problem
with no episodes of febrile neutropenia. Nephrotoxicity did not
occur.
Symptomatic responses; change in performance status
There was a good symptomatic response to MVP chemotherapy
(Table 2). Of the 11 patients who were randomized to receive
chemotherapy, three were asymptomatic at the start of treatment
and remained that way throughout the three cycles. The other eight
patients initially had a variety of symptoms including dyspnoea,
cough, haemoptysis and pain. All eight had symptomatic improve-
ment: four had a complete symptomatic response, and the other
four had a partial response. No patient deteriorated.
Two of 11 patients experienced an improvement in performance
status, both patients improving from PS 1 to PS 0. In both cases
this improvement occurred between cycles 2 and 3. The other nine
patients were stable throughout the three cycles. No deterioration
in performance status occurred.
Objective responses
Of the 11 patients receiving chemotherapy, six (55%) had a partial
response (Table 2). The percentage reduction in the product of
perpendicular diameters ranged from 50% to 82%. Three patients
had a minor response (percentage reduction 29% to 46%), and two
patients demonstrated no change in the size of their tumour. No
patients had evidence of progressive disease during the treatment.
Of the six responding patients, three had squamous carcinoma,
two had adenocarcinoma and one had undifferentiated carcinoma.
All six were stage IB prior to treatment. The two patients who had
no response to chemotherapy had squamous cell histology, one
being stage IB and the other stage IIB.
Surgical results
Of the 11 patients receiving immediate surgery, three had a single
lobectomy, two had a bilobectomy, four had pneumonectomies 
and two had a lobectomy with resection of chest wall. Of the 10
patients who had surgery following chemotherapy, five had single
lobectomies, two had bilobectomies, one had a pneumonectomy,
one had a lobectomy with chest wall resection, and one underwent
a sleeve resection of the main bronchus in addition to a lobectomy.
The surgery was tolerated well. There appeared to be no addi-
tional technical difficulties in the surgery performed on the
patients who had received chemotherapy. There were no signifi-
cant differences in the peri-operative and post-operative problems
seen in the patients from each of the two arms. However, one
patient in the chemotherapy arm did develop adult respiratory
distress syndrome (ARDS) post-operatively and required a
prolonged admission in intensive care before recovering. He had
continuing problems with empyema post-discharge.
Pathological findings
No patient had a pathological complete response. A partial patho-
logical response was seen in five of 10 assessable patients (Table
3): three of these five were found to have minimal residual tumour,
two having only small single nodules of tumour tissue remaining;
the other two patients with a partial response had large areas of
tumour necrosis.
Quality of life
Quality of life analysis in patients receiving pre-operative
chemotherapy showed that mean scores in four of the five func-
Table 1 Patient characteristics by treatment group
Characteristic Chemotherapy Surgery alone
Sex
Male 9 8
Female 2 3
Median age (years) 67 (44–77) 60 (51–77)
TNM Stage
IA 0 0
IB 9 10
IIA 0 0
IIB 1 1
IIIA 1 0
Performance status (WHO)
02 5
19 6
Weight loss
Not significant 10 11
> 5% of pre-illness weight 1 0
Histology
Squamous cell carcinoma 7 5
Adenocarcinoma 2 4
Other (carcinoma/anaplastic/necrotic 2 2
mixed)
Table 2 Responses in pre-operative chemotherapy patients (n = 11)
Response Symptomatic Radiological
Complete response 4 (36%) 0
Partial response 4 (36%) 6 (55%)
Minor response 0 3 (28%)
Asymptomatic/no change 3 (28%) 2 (17%)
Progressive disease 0 0
Table 3 Pathological response post-chemotherapy (n = 10)
Pathological complete response 0
Pathological partial response
Minimal residual tumour 3
Large areas of necrosis 2
No apparent change 5Pre-operative chemotherapy in early stage NSCLC 1517
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tioning QOL scales had either improved slightly (Emotional and
Cognitive Functioning), or remained stable (Physical and Role
Functioning), following chemotherapy. None of the changes
reached statistical significance. There was a small, but non-signif-
icant, decrease in Social Functioning (Table 4).
In the same patients, following surgery, there was a decrease in
all the functioning QOL scale scores, with the largest decrease in
the Social Functioning scale; again, none of these decreases
reached significance (Table 4). Although an attempt was made to
measure quality of life in the surgery-only patients, poor patient
compliance with post-surgery questionnaires meant that mean-
ingful analysis of this group was not possible.
DISCUSSION
This study has confirmed that the administration of three cycles of
MVP chemotherapy prior to surgery in patients with early stage
NSCLC (IB and II as well as IIIA) is feasible, with 55% of eligible
patients agreeing to participate. All patients randomized complied
with the full treatment schedule. As previously shown in patients
with stage IV NSCLC (Ellis et al, 1995), the MVP regimen proved
to be easy to administer, and had minimal toxicity. There were no
grade III/IV toxicities, and the most common toxicities were minor
(grade I) nausea and lethargy. There were no dose reductions
required for either haematological or nephro-toxicity. There were
also no treatment delays, an important issue in a potentially
curable tumour, with surgery proceeding as planned in all appro-
priate cases.
Although potential concerns have been voiced about delaying
surgery during pre-operative chemotherapy, we found no evidence
of disease progression during chemotherapy. Indeed, there was 
a suggestion that those patients receiving pre-operative
chemotherapy required less extensive operations than those
proceeding directly to surgery. This suggests that the benefit of
chemotherapy-induced tumour regression outweighs the theoret-
ical risk of tumour progression, a key point for confirmation in a
phase III trial.
In this context, five patients showed pathological evidence of
tumour regression, with two of the patients having only small
residual nodules of tumour present in the surgical specimen. In this
small series, no complete pathological remissions were seen, but
these have been reported in other series. Martini et al (1993) found
a 14% pathological complete response rate in 136 patients with N2
disease following two to three cycles of MVP chemotherapy.
Rosell et al (1994) reported one complete response, and four cases
with only residual microscopic tumour foci in 30 stage IIIA
patients treated with three cycles of pre-operative mitomycin-C,
ifosfamide and cisplatin.
A further useful benefit for pre-operative chemotherapy was the
improvement in cancer-related symptoms prior to surgery. All
patients who had symptoms at the time of randomization
responded to chemotherapy, with half of them having a complete
response. Two patients had improvement in their performance
status, whilst the other nine remained stable. Patients receiving
chemotherapy therefore arrived for surgery at least as fit as those
proceeding directly to surgery, and sometimes fitter. We have also
reported good symptomatic benefit from MVP in patients
receiving chemotherapy for advanced, metastatic NSCLC (Ellis et
al, 1995).
Quality of life data on the Physical, Role, Emotional, Cognitive
and Social Functioning scales likewise suggested no significant
deterioration during chemotherapy. It was of interest that surgery
appeared to have a greater detrimental effect than chemotherapy,
and this needs formal testing in a phase III trial.
A theoretical concern of pre-operative chemotherapy is
increased peri-operative complications secondary to potential
toxic effects of the drugs on pulmonary tissue. This particularly
applies to the use of mitomycin-C, which has known pulmonary
toxicity, but nearly always at larger cumulative doses than used
here (Doyle et al, 1984; Linette et al, 1992). Although the numbers
in this pilot study are too small to make definite conclusions, there
did not appear to be a significant increase in peri-operative
complications in the patients in the chemotherapy-treatment arm.
Other randomized trials of preoperative chemotherapy have also
not found a significant increase in surgical complications in the
chemotherapy arm (Rosell et al, 1994; Roth et al, 1994).
In conclusion, the results of this small pilot randomized phase II
study have shown that this approach is acceptable to more than
50% of eligible patients; the MVP chemotherapy regimen is well
tolerated and brings patients to surgery with improved symptom
control and, in some cases, improved performance status. We did
not encounter disease progression or other adverse events during
the chemotherapy or at surgery. The study therefore justifies a
large multi-centre phase III trial in all patients with operable
NSCLC to see whether the survival benefit suggested with pre-
operative chemotherapy in the small randomised stage IIIA
NSCLC trials can be confirmed. Such a trial is now underway
under the auspices of the Medical Research Council Lung Group,
and the data will be included in the currently running UK Big
Lung Trial. Lung cancer specialists are invited to join.
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